The Next Big Biotech Breakout
HENDERSON, NV / ACCESSWIRE / January 8, 2019 / Celgene's major deal with Bristol-Myers Squibb seems to have woken up the sleeping giant that is the biotech market. Axsome announced positive trial data and nearly tripled in price Monday. We've been on the hunt for the next biotech to pop.
One promising opportunity we like, Endonovo Therapeutics, Inc. (ENDV), has several non-invasive therapies tackling everything from pain management to degenerative joint diseases. The company just announced a deal that will add up to $10 million in working capital to their balance sheet which could amplify the company's already rapid growth. Do your due diligence on ENDV, it may be the next big winner in the biotech industry.
We are highlighting: Endonovo Therapeutics, Inc. (ENDV), Axsome Therapeutics, Inc. (AXSM), Histogenics Corporation (HSGX), Aevi Genomic Medicine, Inc. (GNMX), and Advaxis, Inc. (ADXS).
The global market for non-opioid pain treatment totaled $9.9 billion in 2017 and is estimated to reach $22.6 billion by 2022, growing at a CAGR of 18.0% for the period of 2017-2022. The aforementioned Endonovo Therapeutics, Inc. (ENDV) (Market Cap: $8.077M, Share Price: $0.0194), a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies, has developed a therapy that has shown to significantly reduce postoperative pain without the kinds of side effects of many other opioid alternatives. Their non-invasive easy to use ORTHOHALO™ device delivers targeted Pulsed ElectroMagnetic Field (tPEMF) therapies to reduce pain and enhance post-surgical recovery, naturally. Its patented non-pharmacologic process uses proprietary technology to reduce pain, swelling, and inflammation.
ENDV's non-invasive therapies are not limited to pain management. The company has several non-invasive products for different conditions. In fact, the company just announced the allowance for the patent application entitled Devices and Method For Treatment Of Degenerative Joint Diseases With Electromagnetic Fields by the U.S. Patent and Trademark Office. Endonovo will be including this technology under its WOUNDPULSE™brand.
ENDV also announced an agreement with Azure Capital that will bring the company up to $10 Million for general corporate purposes, including working capital. This is a major development that could expedite the company's growth.
Now is the time to start your research on ENDV.
____
Axsome Therapeutics, Inc. (AXSM)(Market Cap: $204.817M, Share Price: $6.87) reminded investors Monday why the biotech sector can be so lucrative. The company shot up 164% in very active premarket trade Monday, after announcing a phase 2 trial of its AXS-05 met its primary endpoint, and "significantly improved symptoms of depression."
____
Histogenics Corporation (HSGX) (Market Cap: $13.323M, Share Price: $0.21) reported an update on their NeoCart regulatory pathway based on discussions with the FDA indicating that an additional trial would need to be completed before it would accept submission of a Biologics License Application for NeoCart.
____
Aevi Genomic Medicine, Inc. (GNMX) (Market Cap: $15.706M, Share Price: $0.24) announced that the ASCEND trial, a genomically-guided Phase 2 double-blind, placebo-controlled clinical trial of orally-administered AEVI-001 (100 - 400 mg BID) in children aged 6 - 17 with Attention Deficit Hyperactivity Disorder (ADHD) with an mGluR copy number variant (Part A) or without an mGluR copy number variant (Part B), did not achieve statistical significance on the primary endpoint of reduction of ADHD-RS in either Part A or Part B after 6 weeks of treatment with AEVI-001. AEVI-001 was safe and well tolerated. Reported adverse events were minimal and similar across both Part A and Part B treatment groups.
____
Advaxis, Inc. (ADXS) (Market Cap: $28.711M, Share Price: $0.41) recently presented at the LD Micro Main Event.
Legal Disclaimer:
This article was written by Regal Consulting, LLC (''Regal Consulting''). Regal consulting has agreed to receive 3 million restricted 144 shares as a signing bonus, and additionally receive $4,000 cash per month, and 1 million restricted 144 shares per month starting 8/23/18, this is a twelve-month agreement, and can be canceled at anytime by the issuer ENDV. All payments were made directly by Endonovo Therapeutics, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. ENDV was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Microspeculators.com Full Legal Disclaimer Click Here.
Contact Information:
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: info@microcapspeculators.com
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/
SOURCE: ACR Communications LLC
